Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

33 results about "Netilmicin" patented technology

Netilmicin is a member of the aminoglycoside family of antibiotics. These antibiotics have the ability to kill a wide variety of bacteria. Netilmicin is not absorbed from the gut and is therefore only given by injection or infusion. It is only used in the treatment of serious infections particularly those resistant to gentamicin.

Separation and purification method of high-purity netilmicin

The invention relates to a separation and purification method of high-purity netilmicin, belonging to the technical fields of medical continuous chromatographic separation and binding film separation and purification. In the invention, the continuous chromatographic separation technology is used for separating and purifying triacetyl sisomicin reaction liquid to obtain high-purity triacetyl sisomicin, and then, the industrial chromatographic separation and film separation combined technology is used for purifying and separating netilmicin hydrolyzate to obtain high-purity netilmicin. By adopting a continuous chromatographic separation system combined with film ultrafiltration and nanofiltration technology, the feed liquid of the triacetyl sisomicin and the netilmicin which are used as intermediates can be effectively separated and purified through the continuous chromatographic separation system; in the film separation production process, the reasonable temperature condition is controlled to reduce the generation of degradation products; and meanwhile, the production cost can be reduced, the production cycle can be shortened, the product quality can be improved, and the discharge amount of waste water can be lowered. The netilmicin purity of the product, which is measured by the high performance liquid chromatography (HPLC) method, is greater than or equal to 98%.
Owner:WUXI FORTUNE PHARMA

Method for simultaneously separation determination of content of three aminoglycoside antibiotics

The invention discloses a method for simultaneously separation determination of the content of three aminoglycoside antibiotics (AGs) (tobramycin, etimicin and netilmicin); the method successfully separates a mixture of the three antibiotics, and also is applied in determination of the content of the AGs in tobramycin eye drops, an etimicin sulfate injection and a netilmicin sulfate injection, and an HPLC-RRS combined technology is used for determination of the AGs. In an experiment, used chromatographic columns comprise Agilent Zorbox SB-C18 column (250 mm*4.6 mm i.d., 5 [mu]m) and a protective column (Security Guard C18, 4*2 mm, Phenomenex). A mobile phase is methanol:water (containing 0.2% TFA)=5:95 (v/v), the HPLC flow rate is 0.50 mL*min<-1>, [lambda]ex=[lambda]em=362 nm, the column temperature is 30 DEG C, and the sample injection volume is 20 [mu]L. The probe is a 2.0*10<-5> mol*L<-1> PSB solution, the pH is 9.5, the single-pump flow rate is 0.2 mL*min<-1>, the reaction pipe length is 250 cm, and the internal diameter is 0.5 mm. A brand-new HPLC detection mode established with RRS as a detection method is established, and is successfully applied to determination of the content of the AGs in different preparations. The application range of the RRS technology is widened, and the brand-new detection mode is provided for HPLC.
Owner:CHONGQING MEDICAL UNIVERSITY

Reagent of multi-residue simultaneous rapid fluorescence detection of aminoglycoside antibiotics and application thereof

ActiveCN110308289AEasy to storeSolve the problem of information transmissionBiological testingFluorescence/phosphorescenceKanamycinAntibiotic Y
The invention relates to a preparation and using method of a reagent of multi-residue simultaneous rapid fluorescence detection of aminoglycoside antibiotics. Three kinds of quantum dots with the samematerial core and different emission wavelengths are coupled with an aptamer having the high specific recognition ability for kanamycin, netilmicin and tobramycin; the three kinds of coupling mattersand graphene oxide to form a fluorescence resonance energy transfer system; and a reagent capable of realizing simultaneous rapid fluorescence detection of kanamycin, netilmicin and tobramycin residues is prepared. With the provided reagent, rapid, accurate and sensitive detection of kanamycin, netilmicin and tobramycin residues in milk samples can be realized without depending on the separationanalysis technology; and the powerful technical guarantee is provided for the g food safety supervision enhancement.
Owner:JIANGSU UNIV

Fructose injection of antibiotic medicine

The invention relates to fructose injection of an antibiotic medicine. The fructose injection of the antibiotic medicine consists of antibiotics, fructose and water and also comprises proper additives, wherein the antibiotics comprise gatifloxacin, levofloxacin, ciprofloxacin, pazufloxacin, fleroxacin, sparfloxacin, moxifloxacin, pefloxacin, rufloxacin, lomefloxacin, norfloxacin, caderofloxacin, azithromycin, telithromycin, ornidazole, secnidazole, tinidazole, metronidazole, clindamycin, lincomycin, fluconazole, etimicin, netilmicin, amikacin as well as medicinal acid addition salt, esterification compounds, derivatives and the like; the fructose injection is prepared from the antibiotics; the advantages that the injection is convenient to use and takes effect rapidly are achieved; and compared with the glucose injection, the fructose injection is easier to absorb and utilize, more suitable for antisepsis and anti-inflammation, energy supply and body liquid supplementation of patientssuffering from diabetes, heart diseases and liver diseases, and enlarges the use range.
Owner:WEIHAI HAOTONG MEDICAL SCI & TECH

Separation and purification method of high-purity netilmicin

The invention relates to a separation and purification method of high-purity netilmicin, belonging to the technical fields of medical continuous chromatographic separation and binding film separation and purification. In the invention, the continuous chromatographic separation technology is used for separating and purifying triacetyl sisomicin reaction liquid to obtain high-purity triacetyl sisomicin, and then, the industrial chromatographic separation and film separation combined technology is used for purifying and separating netilmicin hydrolyzate to obtain high-purity netilmicin. By adopting a continuous chromatographic separation system combined with film ultrafiltration and nanofiltration technology, the feed liquid of the triacetyl sisomicin and the netilmicin which are used as intermediates can be effectively separated and purified through the continuous chromatographic separation system; in the film separation production process, the reasonable temperature condition is controlled to reduce the generation of degradation products; and meanwhile, the production cost can be reduced, the production cycle can be shortened, the product quality can be improved, and the discharge amount of waste water can be lowered. The netilmicin purity of the product, which is measured by the high performance liquid chromatography (HPLC) method, is greater than or equal to 98%.
Owner:WUXI FORTUNE PHARMA

Sustained-release injection containing netilcosin

A sustained-release injection containing netilmicin comprises sustained-release microspheres and solvent. The microspheres contain sustained-release adjuvants and aminoglycoside antibiotics, and the solvent is a special solvent containing suspending agent such as sodium carboxymethylcellulose and having viscosity of 100-3000cp (20-30 DEG C); and the sustained-release adjuvants are selected from poly(ethylene-co-vinylacetate) (EVAc), polifeprosan, poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), sebacic acid copolymer, albumin glue and gelatin; the sustained-release microspheres can also be made into sustained-release implant or ointment. The sustained-release implant or injection can be locally placed or injected into foci to locally sustained-release of drug for 5-30 days, so as to obtain and maintain local drug effective concentration while remarkably reduce the systemic toxicity of the drug. The sustained-release injection has distinct and unique therapeutic effect on local infection diseases caused by Staphylococci, Streptococci, Peptostreptococcus, Propionibacterium acnes, Enterobacter, Mycobacterium tuberculosis, Gonococcus or Meningococcus, such as chronic osteomyelitis, severe decubital ulcer, refractory skin ulcer, diabetic foot, femoral head necrosis, abscess, etc.
Owner:JINAN SHUAIHUA PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products